Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Operator: Good morning, ladies and gentlemen, and welcome to the Scholar Rock Second Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded […] ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

Explore Scholar Rock Holding stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SRRK.

Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary ...

Norman Finkelstein, a political scientist and activist known for his fiery on-air criticisms of Israel’s ongoing genocide in ...

Anyone who’s attended college knows juggling a hefty schedule and making time for a social life can be hard, but one UA ...

Chinese scientists uncovered a powerful energy source for deep Earth microbes: hydrogen and oxidants generated by rock ...